US FDA closed out the month of April with two new molecular entity approvals that address underserved markets but carry some safety concerns.

Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.

Addressing health care inequities, providing a nurturing environment for employees and learning from the pandemic were among the aims expressed by executives surveyed by Scrip.

Phase III data showed that the first-in-class oral antifungal can prevent recurrence of vaginal yeast infections, a potentially valuable label addition to the current indication for acute treatment.